Merck (BUE:MRK) Cyclically Adjusted Revenue per Share: ARS (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BUE:MRK Merck & Co Inc BUE:MRK
66 GF Score
Price ARS47,860.00
GF Value ARS39,099.32
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Merck Cyclically Adjusted Revenue per Share?

Merck BUE:MRK -0.30% 66 Cyclically Adjusted Revenue per Share is ARS as of Jun. 2026. GuruFocus rates BUE:MRK with a GF Score™ of 66/100 and a GF Value™ of ARS39,099.32 (Modestly Overvalued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Merck's adjusted revenue per share for the three months ended in Jun. 2026 was ARS1,891.496. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ARS for the trailing ten years ended in Jun. 2026.

During the past 12 months, Merck's average Cyclically Adjusted Revenue Growth Rate was 7.00% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 5.90% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 6.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Merck was 17.80% per year. The lowest was -2.50% per year. And the median was 3.40% per year.

As of today (2026-09-22), Merck's current stock price is ARS47860.00. Merck's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ARS. Merck's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.68.


Merck  (BUE:MRK) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Merck was 6.58. The lowest was 3.32. And the median was 4.68.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Merck Cyclically Adjusted Revenue per Share Related Terms


Merck Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Merck's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Merck Cyclically Adjusted Revenue per Share Chart

Merck Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Merck Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

BUE:MRK vs ABBV, AMGN, GILD: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - General subindustry, Merck's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Merck Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Merck's Cyclically Adjusted PS Ratio falls into.


BUE:MRK
66GF Score
Merck & Co Inc BUE:MRK
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Merck Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Merck's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1891.496/333.9520*333.9520
=1,891.496

Current CPI (Jun. 2026) = 333.9520.

Merck Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 11.258 241.428 15.572
201612 11.197 241.432 15.488
201703 10.580 243.801 14.492
201706 11.291 244.955 15.393
201709 13.051 246.819 17.658
201712 13.497 246.524 18.284
201803 14.739 249.554 19.724
201806 17.969 251.989 23.814
201809 25.642 252.439 33.922
201812 30.958 251.233 41.151
201903 32.314 254.202 42.452
201906 39.666 256.143 51.715
201909 48.285 256.759 62.802
201912 54.766 256.974 71.171
202003 58.012 258.115 75.057
202006 49.640 257.797 64.304
202009 62.894 260.280 80.696
202012 68.994 260.474 88.457
202103 73.421 264.877 92.568
202106 83.985 271.696 103.229
202109 100.543 274.310 122.404
202112 110.532 278.802 132.396
202203 134.298 287.504 155.995
202206 137.402 296.311 154.856
202209 162.392 296.808 182.715
202212 158.856 296.797 178.743
202303 220.565 301.836 244.034
202306 275.393 305.109 301.427
202309 392.167 307.789 425.502
202312 490.175 306.746 533.650
202403 1,036.552 312.332 1,108.303
202406 1,124.157 314.175 1,194.922
202409 1,237.898 315.301 1,311.123
202412 1,204.828 315.605 1,274.868
202503 1,302.754 319.799 1,360.409
202506 1,444.477 322.561 1,495.488
202509 1,827.702 324.800 1,879.202
202512 1,885.757 324.054 1,943.356
202603 1,858.555 330.213 1,879.599
202606 1,891.496 333.952 1,891.496

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ARS mean?
Merck (BUE:MRK) has a Cyclically Adjusted Revenue per Share of ARS as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors.
Is Merck's Cyclically Adjusted Revenue per Share too high?
Merck's current Cyclically Adjusted Revenue per Share is ARS. Overall, Merck has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Merck's Cyclically Adjusted Revenue per Share compare to ABBV and AMGN?
Merck's Cyclically Adjusted Revenue per Share of ARS can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Merck and its competitors. Merck's current Cyclically Adjusted Revenue per Share is ARS. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Based on GuruFocus' analysis, Merck (BUE:MRK) is currently considered Modestly Overvalued. The stock's GF Value™ is ARS39,099.32, compared to a current price of ARS47,860.00 — trading 22.4% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ARS. Merck's overall GF Score™ is 66/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Merck (BUE:MRK), the current Cyclically Adjusted Revenue per Share is ARS as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Merck (BUE:MRK) Overvalued in 2026?

Based on GuruFocus' analysis, Merck stock appears to be overvalued. The current stock price of ARS47,860.00 is trading 22.4% above its estimated GF Value™ of ARS39,099.32. GuruFocus considers Merck to be Modestly Overvalued.

Key valuation signals for BUE:MRK:

  • Cyclically Adjusted Revenue per Share: ARS
  • GF Value™: ARS39,099.32 vs. price of ARS47,860.00 (22.4% above fair value)
  • GF Score™: 66/100 with 8 warning signs

No single metric tells the full story. See the BUE:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Merck Business Description

Address 126 East Lincoln Avenue, Rahway, NJ, USA, 07065
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
66GF Score

Get the complete analysis for BUE:MRK

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

ARS47,860.00
Price
ARS39,099.32
GF Value